Human Trials

Lynparza delivers OS benefit in PROfound trial in prostate cancer

AstraZeneca and Merck said that their co-developed cancer drug Lynparza (olaparib) demonstrated overall survival (OS) benefit in a phase 3 trial in a certain patient population with prostate cancer.

AstraZeneca, Saint Luke’s Mid America Heart Institute begin COVID-19 trial with Farxiga

AstraZeneca, along with the Saint Luke’s Mid America Heart Institute, has commenced a phase III DARE-19 study with Farxiga (dapagliflozin) in COVID-19 patients.

Emergex signs agreement with George Mason University for highly pathogenic RNA virus studies

Emergex Vaccines Holding, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, today announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.

Hope Biosciences announces third FDA-approved clinical trial for COVID-19

Hope Biosciences announces FDA approval on their third clinical trial for COVID-19.

Opdivo, Yervoy combo meets primary endpoint in phase 3 malignant pleural mesothelioma trial

Bristol-Myers Squibb (BMS) said that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) met the primary endpoint of a phase 3 trial in previously untreated malignant pleural mesothelioma (MPM).

Alexion announces plans to initiate Phase 3 Study of ULTOMIRIS (ravulizumab-cwvz) in hospitalised patients with severe COVID-19

Alexion Pharmaceuticals announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS).

Novartis to study hydroxychloroquine in hospitalised COVID-19 patients

Novartis has entered into an agreement with the US Food and Drug Administration (FDA) to conduct a clinical trial with the hydroxychloroquine in hospitalised COVID-19 patients.

Ascendis’ TransCon PTH shows promise in phase 2 hypoparathyroidism trial

Ascendis Pharma said that its prodrug candidate TransCon PTH has met key objectives in the phase 2 PaTH Forward trial in adult subjects with hypoparathyroidism.

Sinovac Biotech to move ahead with COVID-19 vaccine trial in China

Sinovac Biotech has secured approval in China to move ahead with a human clinical trial on an inactivated vaccine candidate against the SARS-CoV-2 virus (novel coronavirus or COVID-19).